» Articles » PMID: 38971841

Production and Stability of Cultured Red Blood Cells Depends on the Concentration of Cholesterol in Culture Medium

Overview
Journal Sci Rep
Specialty Science
Date 2024 Jul 6
PMID 38971841
Authors
Affiliations
Soon will be listed here.
Abstract

The production of cultured red blood cells (cRBC) for transfusion purposes requires large scale cultures and downstream processes to purify enucleated cRBC. The membrane composition, and cholesterol content in particular, are important during proliferation of (pro)erythroblasts and for cRBC quality. Therefore, we tested the requirement for cholesterol in the culture medium during expansion and differentiation of erythroid cultures with respect to proliferation, enucleation and purification by filtration. The low cholesterol level (22 µg/dl) in serum free medium was sufficient to expand (pro)erythroblast cultures. Addition of 2.0 or 5.0 mg/dL of free cholesterol at the start of differentiation induction inhibited enucleation compared to the default condition containing 3.3 mg/dl total cholesterol derived from the addition of Omniplasma to serum free medium. Addition of 5.0 mg/dl cholesterol at day 5 of differentiation did not affect the enucleation process but significantly increased recovery of enucleated cRBC following filtration over leukodepletion filters. The addition of cholesterol at day 5 increased the osmotic resistance of cRBC. In conclusion, cholesterol supplementation after the onset of enucleation improved the robustness of cRBC and increased the yield of enucleated cRBC in the purification process.

References
1.
Landsteiner K, WIENER A . STUDIES ON AN AGGLUTINOGEN (Rh) IN HUMAN BLOOD REACTING WITH ANTI-RHESUS SERA AND WITH HUMAN ISOANTIBODIES. J Exp Med. 2009; 74(4):309-20. PMC: 2135190. DOI: 10.1084/jem.74.4.309. View

2.
Gassner C, Castilho L, Chen Q, Clausen F, Denomme G, Flegel W . International Society of Blood Transfusion Working Party on Red Cell Immunogenetics and Blood Group Terminology Report of Basel and three virtual business meetings: Update on blood group systems. Vox Sang. 2022; 117(11):1332-1344. PMC: 10680040. DOI: 10.1111/vox.13361. View

3.
Pirenne F, Floch A, Diop S . Alloimmunisation against red blood cells in sickle cell disease: transfusion challenges in high-income and low-income countries. Lancet Haematol. 2023; 10(6):e468-e476. DOI: 10.1016/S2352-3026(23)00066-2. View

4.
Giarratana M, Rouard H, Dumont A, Kiger L, Safeukui I, Le Pennec P . Proof of principle for transfusion of in vitro-generated red blood cells. Blood. 2011; 118(19):5071-9. PMC: 3217398. DOI: 10.1182/blood-2011-06-362038. View

5.
Hawksworth J, Satchwell T, Meinders M, Daniels D, Regan F, Thornton N . Enhancement of red blood cell transfusion compatibility using CRISPR-mediated erythroblast gene editing. EMBO Mol Med. 2018; 10(6). PMC: 5991592. DOI: 10.15252/emmm.201708454. View